Does Routine Anti-Osteoporosis Medication Lower the Risk of Fractures in Male Subjects? An Updated Systematic Review With Meta-Analysis of Clinical Trials

作者：Lingfeng Zeng, Bi-Qi Pan, Gui-Hong Liang, Minghui Luo, Ye Cao, Da Guo, Hongyun Chen, Jianke Pan, Hetao Huang, Qiang Liu, Zi-Tong Guan, Yanhong Han, Di Zhao, Jinlong Zhao, Sen-Rong Hou, Ming Wu, Jiongtong Lin, Jiahui Li, Weixiong Liang, Aihua Ou, Qi Wang, Weiyi Yang, Jun Liu · 发表于：Frontiers in Pharmacology · 年份：2019 · DOI：10.3389/fphar.2019.00882 · 被引用次数：23 · 研究领域：Bone health and osteoporosis research、Hip and Femur Fractures、Bone health and treatments

Background: Several epidemiological articles have reported the correlations between anti-osteoporosis medication and the risks of fractures in male and female subjects, but the specific efficacy of anti-osteoporosis medication for male subjects remains largely unexplored. Objective: The aim of this study was to evaluate the correlation between anti-osteoporosis medication and the risk of fracture in relation to low bone mass (including outcomes of osteoporosis, fracture and BMD loss) in male subjects analyzed in studies within the updated literature. Methods: Randomized Controlled Trials (RCTs) that analyzed the effectiveness of a treating prescription for male subjects with osteoporosis (or low BMD) and that focused on the outcomes of fracture were included. Relevant studies from EmBase, Web of Science, PubMed and Chinese database of CNKI were retrieved from inception to January 30th, 2019. Two staff members carried out the eligibility assessment and data extraction. The discrepancies were settled by consultation with another researcher. We calculated the pooled relative risks (RRs) based on 95% confidence intervals (CIs). Results: Twenty-seven documents (28 studies) with 5,678 subjects were identified. For the category of bisphosphonates, significant results were observed in pooled analyses for decreased risk of the vertebral fractures domain (RR, 0.44 [95%CI, 0.31–0.62]), nonvertebral fractures domain (RR, 0.63 [95%CI, 0.46–0.87]), and clinical fractures domain (RR, 0.59 [...